Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Change in Account Payables (2023 - 2025)

Historic Change in Account Payables for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to -$2.3 million.

  • NewAmsterdam Pharma's Change in Account Payables fell 21910.76% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.6 million, marking a year-over-year decrease of 21473.11%. This contributed to the annual value of -$12.9 million for FY2024, which is 35538.46% down from last year.
  • According to the latest figures from Q3 2025, NewAmsterdam Pharma's Change in Account Payables is -$2.3 million, which was down 21910.76% from -$391000.0 recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma's Change in Account Payables registered a high of $12.9 million during Q4 2023, and its lowest value of -$9.2 million during Q3 2023.
  • Its 3-year average for Change in Account Payables is -$753363.6, with a median of -$2.3 million in 2025.
  • The largest annual percentage gain for NewAmsterdam Pharma's Change in Account Payables in the last 5 years was 12708.46% (2025), contrasted with its biggest fall of 21910.76% (2025).
  • NewAmsterdam Pharma's Change in Account Payables (Quarter) stood at $12.9 million in 2023, then tumbled by 124.79% to -$3.2 million in 2024, then increased by 29.03% to -$2.3 million in 2025.
  • Its last three reported values are -$2.3 million in Q3 2025, -$391000.0 for Q2 2025, and $2.3 million during Q1 2025.